Weekly injection trial aims to halt debilitating heart disease

NCT ID NCT03702829

Summary

This study tested whether weekly injections of a drug called inotersen could slow or stop the progression of a serious heart condition called TTR amyloid cardiomyopathy. The drug works by reducing the production of a problematic protein that builds up and damages the heart. Over 24 months, researchers monitored 31 patients with this condition to see if the treatment was safe and if it helped preserve heart function compared to what typically happens without it.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

Conditions

Explore the condition pages connected to this study.